HERC2P9 Gene as Potential Drug Target for Cancer, Neurodegerative Diseases and Autoimmune Disorders

Target Name: HERC2P9

NCBI ID: G440248

HERC2P9

Other Name(s): HERC2 pseudogene 9

HERC2P9 Gene as Potential Drug Target for Cancer, Neurodegerative Diseases and Autoimmune Disorders

HERC2P9, also known as HERC2 pseudogene 9, is a gene that encodes a protein known as protocellin-1 (P1). P1 is a transmembrane protein that is involved in several cellular processes, including cell signaling, cell adhesion, and cytoskeletal organization. The HERC2P9 gene has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The HERC2P9 gene

The HERC2P9 gene is located on chromosome 1p36.2 and has a length of 1,158 base pairs. The gene encodes a 154 amino acid protein that consists of a single transmembrane domain and a cytoplasmic tail. The transmembrane domain of P1 contains a putative N-terminus and a putative C-terminus. The N-terminus of P1 contains a 尾-sheet that is involved in protein-protein interactions and the C-terminus contains a 纬-helix that is involved in the formation of a disulfide bond.

The P1 protein

The P1 protein is a transmembrane protein that is involved in several cellular processes. It is involved in cell signaling, cell adhesion, and cytoskeletal organization. P1 can interact with several other proteins, including the neurotransmitter GABA, the cytoskeleton protein 伪-actinin, and the cell adhesion molecule E-cadherin.

In addition to its role in cellular signaling, P1 is also involved in the regulation of cell adhesion. P1 can interact with the adhesion molecule E-cadherin and help to regulate the formation of tight junctions between cells. This is important for maintaining tissue structure and function, as well as for ensuring the proper exchange of nutrients and waste products between cells.

P1 is also involved in cytoskeletal organization. It is a member of the tubulin family and is involved in the regulation of microtubule dynamics and stability. This is important for cell movement, as well as for the proper formation of organelles in the cell.

Disease associations

The HERC2P9 gene has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, the HERC2P9 gene has been shown to be involved in the regulation of cell signaling and cell adhesion. Several studies have shown that cancer cells can develop Resistance to chemotherapy by inhibiting the activity of the HERC2P9 gene. Therefore, targeting the HERC2P9 gene may be an effective way to treat cancer.

In neurodegenerative diseases, the HERC2P9 gene has been shown to be involved in the regulation of cell signaling and cell adhesion. Several studies have shown that neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are associated with reduced levels of the HERC2P9 gene. Therefore , targeting the HERC2P9 gene may be an effective way to treat neurodegenerative diseases.

In autoimmune disorders, the HERC2P9 gene has been shown to be involved in the regulation of cell signaling and cell adhesion. Several studies have shown that autoimmune disorders, such as rheumatoid arthritis and ulcerative colitis, are associated with reduced levels of the HERC2P9 gene. Therefore , targeting the HERC2P9 gene may be an effective way to treat autoimmune disorders.

Targeting the HERC2P9 gene

Several studies have shown that targeting the HERC2P9 gene can be an effective way to treat cancer, neurodegenerative diseases, and autoimmune disorders.

One approach to targeting the HERC2P9 gene is to use small molecules to inhibit its

Protein Name: HERC2 Pseudogene 9

The "HERC2P9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HERC2P9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets